In Vitro and in Vivo Studies in Rats with LY293558 Suggest AMPA/kainate Receptor Blockade As a Novel Potential Mechanism for the Therapeutic Treatment of Anxiety Disorders

Overview

Journal Psychopharmacology (Berl)

Specialty Pharmacology

Date 2006 Feb 14

PMID 16470401

Citations 9

Authors

Andrew Alt

Brianne Weiss

Ann Marie Ogden

Xia Li

Scott D Gleason

David O Calligaro

David Bleakman

Jeffrey M Witkin

Affiliations

Soon will be listed here.

Abstract

Rationale: Although convergent evidence exists for a role of glutamate in the regulation of anxiety, the involvement of specific glutamate receptor subtypes has yet to be defined.

Objective: To evaluate the potential for blockade of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA)/kainate receptors to produce anxioltyic-like effects with the AMPA/GLU(K5) (kainate) antagonist (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5yl)ethyl]decahydroisoquinoline-3carboxylic acid (LY293558)

Materials And Methods: Punished responding of rats was used to determine the efficacy of LY293558. Other in vivo and in vitro studies further characterized the specificity of LY293558 for AMPA/kainate receptors.

Results: LY293558 had a rank order of potency of GLU(K5) > or = GLU(K5/6) approximately GLU(A2i) approximately GLU(K2/5) approximately GLU(A1i) approximately GLU(A2o) approximately GLU(A3i) approximately GLU(A1o) > or = GLU(A3o) > or = GLU(A4i) approximately GLU(A4o) and >100 microM affinity for rat cortical GABA(A) receptors. Comparison of the blockade of AMPA- vs N-methyl-D-aspartate (NMDA)-induced inward currents demonstrated that LY293558 was five-fold more potent as an antagonist at AMPA vs NMDA receptors in vitro. In keeping with the low affinity of LY293558 for NMDA receptors, LY293558 was not effective in preventing NMDA-induced seizures in mice. LY293558 increased punished responding, a preclinical predictor of anxiolytic efficacy, at a dose that decreased unpunished responding (10 mg/kg, i.p.). Chlordiazepoxide produced comparable increases in both punished and unpunished responding. The NMDA antagonist dizocilpine [(+)-MK-801] also increased both punished and unpunished responding.

Conclusions: These data along with those in the literature suggest that AMPA and/or kainate receptor blockade may be an important component to producing anxiolytic-like effects and may therefore be a target for compounds with efficacy in the therapeutic treatment of anxiety disorders.

Citing Articles

Sleep Deprivation-Induced Anxiety Alleviated by Oral Administration of 4-Aminopyridine in Male Mice.

Hosseini E Brain Behav. 2025; 15(3):e70382.

PMID: 40059459 PMC: 11891258. DOI: 10.1002/brb3.70382.

Neurotransmitter and tryptophan metabolite concentration changes in the complete Freund's adjuvant model of orofacial pain.

Cseh E, Veres G, Kortesi T, Polyak H, Nanasi N, Tajti J J Headache Pain. 2020; 21(1):35.

PMID: 32316909 PMC: 7175490. DOI: 10.1186/s10194-020-01105-6.

A comparative assessment of two kynurenic acid analogs in the formalin model of trigeminal activation: a behavioral, immunohistochemical and pharmacokinetic study.

Veres G, Fejes-Szabo A, Zadori D, Nagy-Grocz G, Laszlo A, Bajtai A J Neural Transm (Vienna). 2016; 124(1):99-112.

PMID: 27629500 DOI: 10.1007/s00702-016-1615-5.

Protein kinase C is essential for kainate-induced anxiety-related behavior and glutamatergic synapse upregulation in prelimbic cortex.

Liu B, Feng J, Wang J CNS Neurosci Ther. 2014; 20(11):982-90.

PMID: 25180671 PMC: 6493007. DOI: 10.1111/cns.12313.

Presynaptic facilitation of glutamate release in the basolateral amygdala: a mechanism for the anxiogenic and seizurogenic function of GluK1 receptors.

Aroniadou-Anderjaska V, Pidoplichko V, Figueiredo T, Almeida-Suhett C, Prager E, Braga M Neuroscience. 2012; 221:157-69.

PMID: 22796081 PMC: 3443632. DOI: 10.1016/j.neuroscience.2012.07.006.

References

Hamill O, Marty A, Neher E, Sakmann B, Sigworth F . Improved patch-clamp techniques for high-resolution current recording from cells and cell-free membrane patches. Pflugers Arch. 1981; 391(2):85-100. DOI: 10.1007/BF00656997. View

Procter M, Houghton A, Faber E, Chizh B, Ornstein P, Lodge D . Actions of kainate and AMPA selective glutamate receptor ligands on nociceptive processing in the spinal cord. Neuropharmacology. 1998; 37(10-11):1287-97. DOI: 10.1016/s0028-3908(98)00136-1. View

Ginski M, Witkin J . Sensitive and rapid behavioral differentiation of N-methyl-D-aspartate receptor antagonists. Psychopharmacology (Berl). 1994; 114(4):573-82. DOI: 10.1007/BF02244987. View

Kent J, Mathew S, Gorman J . Molecular targets in the treatment of anxiety. Biol Psychiatry. 2002; 52(10):1008-30. DOI: 10.1016/s0006-3223(02)01672-4. View

Krystal J, DSouza D, Petrakis I, Belger A, Berman R, Charney D . NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders. Harv Rev Psychiatry. 1999; 7(3):125-43. View

Liljequist S . Evidence for an anxiogenic action of AMPA receptor antagonists in the plus-maze test. Eur J Pharmacol. 1995; 279(2-3):171-7. DOI: 10.1016/0014-2999(95)00153-c. View

GELLER I . RELATIVE POTENCIES OF BENZODIAZEPINES AS MEASURED BY THEIR EFFECTS ON CONFLICT BEHAVIOR. Arch Int Pharmacodyn Ther. 1964; 149:243-7. View

Schoepp D, Lodge D, Bleakman D, Leander J, Tizzano J, Wright R . In vitro and in vivo antagonism of AMPA receptor activation by (3S, 4aR, 6R, 8aR)-6-[2-(1(2)H-tetrazole-5-yl) ethyl] decahydroisoquinoline-3-carboxylic acid. Neuropharmacology. 1995; 34(9):1159-68. DOI: 10.1016/0028-3908(95)00099-r. View

Gilron I, Max M, Lee G, Booher S, Sang C, Chappell A . Effects of the 2-amino-3-hydroxy-5-methyl-4-isoxazole-proprionic acid/kainate antagonist LY293558 on spontaneous and evoked postoperative pain. Clin Pharmacol Ther. 2000; 68(3):320-7. DOI: 10.1067/mcp.2000.108677. View

10.

Witkin J . Behavioral effects and anticonvulsant efficacies of low-affinity, uncompetitive NMDA antagonists in mice. Psychopharmacology (Berl). 1999; 146(3):280-9. DOI: 10.1007/s002130051118. View

11.

Kelleher R, Morse W . Determinants of the specificity of behavioral effects of drugs. Ergeb Physiol. 1968; 60:1-56. DOI: 10.1007/BFb0107250. View

12.

Skolnick P . Modulation of glutamate receptors: strategies for the development of novel antidepressants. Amino Acids. 2002; 23(1-3):153-9. DOI: 10.1007/s00726-001-0121-7. View

13.

Vanover K . Effects of AMPA receptor antagonists on dopamine-mediated behaviors in mice. Psychopharmacology (Berl). 1998; 136(2):123-31. DOI: 10.1007/s002130050547. View

14.

Witkin J, Leander J . Effects of the appetite stimulant chlordimeform on food and water consumption of rats: comparison with chlordiazepoxide. J Pharmacol Exp Ther. 1982; 223(1):130-4. View

15.

Chojnacka-Wojcik E, Klodzinska A, Pilc A . Glutamate receptor ligands as anxiolytics. Curr Opin Investig Drugs. 2002; 2(8):1112-9. View

16.

Schoepp D, Salhoff C, Fuson K, Sacaan A, Tizzano J, Ornstein P . Selective protection against AMPA- and kainate-evoked neurotoxicity by (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahyd roisoquinoline- 3-carboxylic acid (LY293558) and its racemate (LY215490). J Neural Transm (Vienna). 1996; 103(8-9):905-16. DOI: 10.1007/BF01291781. View

17.

Ornstein P, ARNOLD M, Augenstein N, Lodge D, Leander J, Schoepp D . (3SR,4aRS,6RS,8aRS)-6-[2-(1H-tetrazol-5-yl)ethyl]decahydroisoquinoline-3 - carboxylic acid: a structurally novel, systemically active, competitive AMPA receptor antagonist. J Med Chem. 1993; 36(14):2046-8. DOI: 10.1021/jm00066a016. View

18.

Sheftell F, Atlas S . Migraine and psychiatric comorbidity: from theory and hypotheses to clinical application. Headache. 2002; 42(9):934-44. DOI: 10.1046/j.1526-4610.2002.02217.x. View

19.

Ploghaus A, Narain C, Beckmann C, Clare S, Bantick S, Wise R . Exacerbation of pain by anxiety is associated with activity in a hippocampal network. J Neurosci. 2001; 21(24):9896-903. PMC: 6763058. View

20.

Huckle R . Pregabalin (Pfizer). Curr Opin Investig Drugs. 2004; 5(1):82-9. View